Document Detail


Interventions for pityriasis rosea.
MedLine Citation:
PMID:  17443568     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Pityriasis rosea is a scaly rash that mainly affects young adults. It can be very itchy but most people recover within 2 to 12 weeks.
OBJECTIVES: To assess the effects of interventions for pityriasis rosea.
SEARCH STRATEGY: We searched the Cochrane Skin Group Specialised Register (December 2004), the Cochrane Central Register of Controlled Clinical Trials in The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to January 2005), EMBASE (1976 to January 2005), LILACS (1982 to January 2005), BIOSIS Preview (1980 to June 2002), and ongoing trials databases. We scanned bibliographies of published studies, abstracts from dermatology conference proceedings, corresponded with trialists and contacted the pharmaceutical industry.
SELECTION CRITERIA: Randomised controlled trials evaluating interventions for pityriasis rosea.
DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. We contacted study authors to retrieve missing data.
MAIN RESULTS: Three trials involving 148 people were included. One poor quality trial (23 people), compared intravenous glycyrrhizin and intravenous procaine. It found no significant difference between the two interventions for treating symptoms and rash. One fair quality trial (85 people), compared the oral antihistamine dexchlorpheniramine (4 mg), the oral steroid betamethasone (500 mcg), and a combination of betamethasone (250 mcg) and dexchlorpheniramine (2 mg). It found no significant difference in itch resolution at two weeks, as rated by the participants, between dexchlorpheniramine and betamethasone, and the combination of dexchlorpheniramine and betamethasone. However, both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash than the combination of dexchlorpheniramine and betamethasone. These interventions were not compared with placebo. The small good quality trial (40 people) that compared oral erythromycin and placebo found that erythromycin was more effective than placebo in terms of rash improvement, as rated by the trialists, after two weeks (RR 13.00; 95% CI 1.91 to 88.64). It was also more effective in decreasing the itch score (difference of 3.95 points, 95% CI 3.37 to 4.53). No serious adverse effects were reported for the interventions. Two out of 17 people on oral erythromycin and 1 out of 17 on placebo reported minor gastrointestinal upset.
AUTHORS' CONCLUSIONS: We found inadequate evidence for efficacy for most treatments for pityriasis rosea. Oral erythromycin may be effective in treating the rash and decreasing the itch. However, this result should be treated with caution since it comes from only one small RCT. More research is necessary to evaluate the efficacy of erythromycin and other treatments.
Authors:
A A T Chuh; B L Dofitas; G G Comisel; L Reveiz; V Sharma; S E Garner; F Chu
Related Documents :
20610978 - Long-term outcome after venom immunotherapy.
19382398 - Dexrazoxane: new indication. anthracycline extravasation: continue using dimethyl sulfo...
18646138 - Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy.
15049018 - Technical aspects in cerebrospinal irradiation.
21461078 - Clinical and virological responses to clevudine therapy of hepatocelluar carcinoma pati...
16303698 - Graves' disease in children and adolescents: response to long-term treatment.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-04-18
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2007  
Date Detail:
Created Date:  2007-04-19     Completed Date:  2007-07-17     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD005068     Citation Subset:  IM    
Affiliation:
Chinese University of Hong Kong, Department of Community and Family Medicine, Shop B5, Ning Yeung Terrace, 78 Bonham Road, Ground Floor, The Mid-Levels,Hong Kong, Hong Kong. achuh@iohk.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Infective Agents / therapeutic use
Erythromycin / therapeutic use
Female
Glycyrrhizic Acid / therapeutic use
Histamine H1 Antagonists / therapeutic use
Humans
Male
Pityriasis Rosea / drug therapy,  therapy*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Anti-Infective Agents; 0/Histamine H1 Antagonists; 114-07-8/Erythromycin; 1405-86-3/Glycyrrhizic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Wholegrain cereals for coronary heart disease.
Next Document:  Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproducti...